Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in MCI with Suspected CTE or AD
NCT06254469Phase 3Recruiting
- Sponsor
- CereMark Pharma
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Flornaptitril in Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE), sponsored by CereMark Pharma. Started Jul 2025; status: recruiting.
02
Drugs
Flornaptitril
03
Conditions
Alzheimer's disease (AD)chronic traumatic encephalopathy (CTE)
Beyond the preview
Go deeper on NCT06254469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254469.